PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1290836
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1290836
Enema Based Products Market size was valued at USD 1,600.7 million in 2022, expanding at a CAGR of 10.7% from 2023 to 2030.
Enema Based Products are effective in treating certain medical conditions. Enemas can serve various functions, including relieving constipation, cleansing the colon before certain medical procedures, administering medications, or delivering nutrients. Some people claim that probiotic enemas help to both eliminate harmful bacteria and increase the number of beneficial bacteria in the colon. However, most oral probiotic supplements tend to contain strains, such as Lactobacillus, that are more resistant to stomach acid. As well, some manufacturers produce oral probiotics with unique delivery systems that are intended to withstand stomach acid and deliver more of the probiotic to the digestive tract.
Colorectal cancer is more prevalent in older individuals. As populations in developed countries continue to age due to advancements in healthcare and improved life expectancy, there is a higher incidence of colorectal cancer. According to the American Society of Clinical Oncology, Worldwide, colorectal cancer is the second leading cause of cancer death. In 2020, an estimated 915,880 people died from colorectal cancer. This includes 576,858 people with colon cancer and 339,022 people with rectal cancer. This high incidence rate is expected to drive demand for enema-based products in the coming years.
The Global Enema Based Products Market is segmented on the basis of Product Type, Application, Technology, and Region.
The market is divided into three categories based on product type: Cleansing, Carminative, Retention, and Return-Flow. Cleansing enemas are commonly used before medical procedures, such as colonoscopies or surgeries, and for constipation relief.
The market is divided into two categories based on application: Hospital and homecare. Hospitals dominate the market and are likely to maintain their dominance during the forecast period. This is partly due to Enema-based products are commonly used in hospitals for several purposes, including Bowel preparation, Constipation management, Medication administration etc.
Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to dominate the growth of Enema Based Products Market, due to the prevalence of gastrointestinal diseases and the growing demand for home care settings. According to American Health Organization, in 2019, digestive disorders accounted for 375,170 deaths, 215,168 deaths in men, and 160,002 deaths in women. Additionally, the national center of biotechnology information, Gastrointestinal (GI) symptoms are widespread and carry heavy economic and social consequences. It is estimated that in the United States, 11% of the population suffers from a chronic digestive disease, with a prevalence rate as high as 35% for those 65 years and over. Enema-based products, when used appropriately under medical supervision, can be beneficial for specific gastrointestinal conditions. Overall, the Enema-Based Products market is expected to experience significant growth in all regions.
Some pharmaceutical companies manufacture and supply enema-based products with their larger portfolio of medical devices and pharmaceuticals. Some of the medical supply companies serve as distributors of enema-based products, sourcing products from various manufacturers and supplying them to hospitals, clinics, and other healthcare facilities. These companies often offer a wide range of medical supplies and devices, including enema kits and related products. Companies trade their products through a variety of channels, including corporate websites, e-commerce websites, retailers, distributors, and end consumers. Products makers compete on a variety of features, including product costs, performance, product making, technology, reputation, and availability.
In May 2023, The US Food and Drug Administration (FDA) granted Vedanta Biosciences' oral microbiome treatment VE303 a fast-track designation for the treatment of recurrent Clostridioides difficile (C.diff) infection, as the company plans to start a Phase III trial later this year, based on a May 8 announcement. According to Vedanta, roughly 500,000 individuals develop C. diff infections every year in the US. C. diff infections cause symptoms such as diarrhoea, fever, and nausea.
The scope of this report covers the market by its major segments, which include as follows: